Neovision Capital
VC Fund
Shanghai, China
Neovision Capital is a VC fund in Shanghai focused on Health Care and Medical. Neovision Capital was founded in 2015. Key founders are from Costone Capital, J.P. Morgan and so on. Leveraging its core team’s rich China-operational experiences, international resources, and business acumen, we are actually dedicated to both early and growth-stage investment in healthcare and TMT sector in China. In order to leverage our coreassets, we actively contribute expertise in essential services including branding, marketing, channel development, overseas expansion, human resources, and finance.
- Total investments:
- 36
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Neovision Capital invests in
Stages Neovision Capital invests in
Countries Neovision Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.4M–$174M
- Series B
- $10M–$90M
Investment Focus
Industry
- Health Care 12 (33%)
- Medical 11 (31%)
- Biotechnology 9 (25%)
- Medical Device 6 (17%)
- Information Technology 5 (14%)
Stage
- Venture - Series Unknown 9 (25%)
- Series A 8 (22%)
- Series B 7 (19%)
- Series C 5 (14%)
- Series D 2 (6%)
Country
- China 31 (86%)
- United States 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Liu Chuanwen
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
|
Qin Yangwen
Managing partner
|
Managing partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $145.4M / Series E / Apr 03, 2026 | ||
|
Nuclide Tongchuang
|
Nuclide Tongchuang is a high-tech enterprise specializing in the research, development, and production of radioisotopes. With advanced technologies and state-of-the-art facilities, the company is committed to providing high-quality isotopic materials and innovative nuclear solutions for applications in medicine, industry, and scientific research. | $60.3M / Series A / Oct 22, 2025 | |
Tongxin Medical Equipment
|
Tongxin makes magnetically-suspended artificial blood pumps which are designed to replace the human heart. They are undergoing clinical trials in China after being fast-tracked through the approval process by the National Medical Products Administration, state-run Xinhua News Agency | $100M / Venture - Series Unknown / Jul 21, 2025 | |
| Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $41.7M / Series C / Mar 14, 2024 | ||
| Zhongbo Ruikang focuses on the research and development of domestic tools in the field of cell and gene therapy, mainly to assist customers in realizing the "continuous, closed, disposable, consistent, scalable, automated, modular, and medical deviceization of cell preparation industrialization. | $13.9M / Series B / Mar 04, 2024 | ||
| Shanghai Electric (Group) Corporation designs, develops, and manufactures thermal, nuclear, and wind power equipment in China. The company offers gas turbines, transmission and distribution equipment, elevators, machine tools, refrigeration compressors, environmental protection equipment, automation products, rail transportation equipment, machineparts, generators, and other products. | $56.7M / Post-IPO Equity / Sep 13, 2023 | ||
| Care Medical is a membrane science platform that focuses on blood purification and biopharmaceuticals. | $13.6M / Series C / Sep 08, 2023 | ||
| Media Center is a technology-based corporation that uses technological innovation to boost industrial upgrading. It enables biotechnology and the bioindustry, the employs automation, artificial intelligence, big data, and industrial Internet technologies. Robot scientists free human scientists' hands, unleash their creativity, and raise thetime and life value of mental workers, intelligent parallel bioreactors accelerate the R&D cycle, save laboratory space, and reduce R&D costs. | $1.4M / Series A / Jul 06, 2023 | ||
| Zhongbo Ruikang focuses on the research and development of domestic tools in the field of cell and gene therapy, mainly to assist customers in realizing the "continuous, closed, disposable, consistent, scalable, automated, modular, and medical deviceization of cell preparation industrialization. | Series A / Jul 15, 2022 | ||
| Dakang Medical is a chain of independent blood purification medical service institutions. Dakang Medical is a company whose leading industries are medical investment, medical institution management, and brand operation services. | $59.7M / Series E / Jun 29, 2022 | ||
| See all 36 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Neovision Capital invest in?
Neovision Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Venture - Series Unknown and Series A stage. Most of the 36 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Neovision Capital's check size?
Neovision Capital typically joins rounds of $1.4M–$174M at Series A and $10M–$90M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Neovision Capital participates in.
How do I contact Neovision Capital?
Public channels for Neovision Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Neovision Capital?
The team at Neovision Capital includes Liu Chuanwen (Managing Director) and Qin Yangwen (Managing partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
